Concord Biotech Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Concord Biotech (NSE: CONCORDBIO) Q4 FY26 results are scheduled for May 10, 2026. Trading at Rs 1,680 as of April 2026 — down -32% from its 52-week high of Rs 2,500 — the stock has been on investors’ watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Concord Biotech.

Q4 (January-March 2026) is the year’s final quarter, bringing full-year FY26 results, management’s FY27 guidance, and the final dividend recommendation — all from a single board meeting on May 10, 2026.

Get free investment predictions from SEBI-registered analysts on Univest.

Concord Biotech Q4 Results 2026 Date

Concord Biotech Q4 FY26 results date is May 10, 2026.

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025-26. Concord Biotech’s board on May 10, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook — making this the single most important results event of the year.

Concord Biotech Q4 FY26 Earnings Estimates

Access premium research on Univest.

Screen Concord Biotech live on the Univest Screener. Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Concord Biotech Q4 FY26 Performance

1. Fermentation Pharma Sector Demand Trends

Concord Biotech’s core Fermentation Pharma business is tracking the broader sector recovery in Q4 FY26. +18% volume YoY trajectory is supported by seasonal demand patterns and end-market growth.

2. Q4 Peak Season Dynamics

Q4 (January-March) is typically a seasonally stronger quarter for most sectors as year-end procurement, construction activity, and consumer buying peak before the monsoon transition.

3. Operating Leverage at Scale

Revenue growth above fixed cost base growth translates to EBITDA margin improvement as the business scales. Q4 volume improvement is the primary operating leverage driver.

4. Management Guidance for FY27

Q4 FY26 results will include management’s first formal commentary on FY27 revenue and margin outlook, which will set the investment narrative for the next 12 months.

5. Balance Sheet and Debt Management

Cash flow generation in Q4 (typically the strongest quarter) supports debt reduction or reinvestment in capacity expansion for FY27.

5 Risks to Watch in Concord Biotech Q4 FY26

Risk 1: Fermentation Pharma Sector Risk

Sector headwinds including input cost pressure, demand cyclicality, and competition could impact Q4 performance.

Risk 2: Revenue Concentration

Customer or geographic concentration creates variance risk.

Risk 3: Regulatory Environment

Policy and regulatory changes in the sector can create compliance or revenue risks.

Risk 4: Working Capital Management

Efficient working capital management determines free cash flow quality in Q4.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions affect end-market demand.

Concord Biotech Share Price and Analyst Ratings

Conclusion

Concord Biotech Q4 FY26 results on May 10, 2026 will reflect Fermentation Pharma sector performance in the January-March 2026 quarter. Revenue above Rs 285 Cr with EBITDA 38% would constitute a beat. The +18% volume YoY trajectory and management FY27 guidance are the primary catalysts for re-rating. At Rs 1,680 — down -32% from its 52-week high of Rs 2,500 — the stock offers a more reasonable entry point than earlier in the year.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Concord Biotech Q4 results 2026 date?

Concord Biotech Q4 FY26 results date is May 10, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.

Q: What is Concord Biotech Q4 FY26 revenue estimate?

Analyst consensus estimate for Concord Biotech Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 242 Cr. Actual Q4 results may differ based on operating conditions.

Q: What is Concord Biotech Q4 FY26 PAT estimate?

Analyst consensus estimate for Concord Biotech Q4 FY26 net profit (PAT) is Rs 68 Cr. Q3 FY26 actual PAT was Rs 57 Cr.

Q: Will Concord Biotech declare a dividend in Q4 FY26?

Concord Biotech is expected to declare Rs 5 for FY26, subject to board approval on May 10, 2026 and shareholder approval at the AGM.

Q: What is Concord Biotech’s current share price?

Concord Biotech is trading at Rs 1,680 as of April 2026, with a 52-week range of Rs 1,380 to Rs 2,500. The 1-year return is -32%.

Q: What were Concord Biotech Q3 FY26 results?

In Q3 FY26, Concord Biotech reported revenue of Rs 242 Cr and PAT of Rs 57 Cr. Q4 FY26 on May 10, 2026 provides the year-end comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.

Q: Is Concord Biotech a good investment ahead of Q4 results?

This article does not constitute investment advice. Concord Biotech trades at Rs 1,680 — down -32% from its peak. Consult a SEBI-registered advisor before investing.

Recent Article

Chembond Chemicals Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Chambal Fertilizers & Chemicals Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Chaman Lal Setia Exports Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Chalet Hotels Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Cerebra Integrated Technologies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook